Pharvaris’ Phase 3 study met its main and secondary goals for preventing HAE attacks, strengthening the case for its lead drug. The drug is still being studied, so the findings do not show it is an established treatment.
That result gives Pharvaris stronger evidence for its lead drug’s ability to prevent HAE attacks. The company is still studying the drug, so the findings do not show it is an established treatment.
Follow Pharvaris (PHVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PHVS